CPA
RNAM

Capital Performance Advisors’s Avidity Biosciences RNAM Stock Holding History

Capital Performance Advisors’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-21
Closed -$965 – 2141
2024
Q3 		$965 Buy
+21
New +$911 ﹤0.01% 1925

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Performance Advisors's RNAM Position: Q4 2024 in Review

Capital Performance Advisors sold out of Avidity Biosciences (RNAM) in Q4 2024, closing a stake of 21 shares — an estimated $965 sold.

Capital Performance Advisors first reported a position in RNAM in Q3 2024 and held it in 1 quarter. The position peaked at $965 in Q3 2024. 236 funds tracked by Wall St. Rank hold RNAM as of Q4 2024.

  • Capital Performance Advisors reported no remaining Avidity Biosciences position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 21 Avidity Biosciences shares in Q4 2024, an estimated $965.
  • Capital Performance Advisors first reported a position in Avidity Biosciences in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Avidity Biosciences position peaked at $965 in Q3 2024.
  • 236 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.